For example, tirzepatide (LY3298176), which is a dual GLP-1R-GIPR agonist, showed superior HbA1c lowering efficacy in patients with T2DM versus GLP-1R agonism alone. Here, GLP1R is linked to type 2 diabetes mellitus.